Healthcare Professionals Section

Prescribing Information PI
procoralan

Important Information

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk.
Adverse events should also be reported to Servier Laboratories Ltd. Tel (01753) 666409

black triangleProcoralan (ivabradine hydrochloride) – Cardiovascular

Procoralan

Licensed indication1:
Symptomatic treatment of chronic stable angina pectoris in coronary artery disease patients with normal sinus rhythm. Procoralan is indicated:

  • in patients unable to tolerate or with a contraindication to the use of beta-blockers
  • or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose and whose heart rate is >60 bpm.

By selectively reducing heart rate, Procoralan increases coronary filling time and oxygen supply therefore reducing myocardial ischaemia2-4.

Procoralan anti-ischaemic efficacy has been shown in monotherapy and in combination with beta-blockers5-6:

  • In monotherapy, Procoralan 7.5mg bd decreases angina attacks by 70% vs baseline5.
  • In combination with beta-blockers, Procoralan improves exercise capacity in comparison with beta-blockers alone6.

 

Prescribing Information PI
procoralan

Important Information

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk.
Adverse events should also be reported to Servier Laboratories Ltd. Tel (01753) 666409

© 2007 LES LABORATOIRES SERVIER, an incorporated company of SERVIER. All Rights Reserved - Terms of Use
SERVIER does not sell its products over the Internet - More information
Last Updated 04/02/2010 17:54:59
Best viewed in Internet Explorer 6.0 or later, at 1024x768 resolution.